Journal of Ophthalmology

Clinical Study

Comparison of Two Botulinum Neurotoxin A Injection Patterns with or without the Medial Lower Eyelid in the Treatment of Blepharospasm

Table 1

Between-group comparisons of ocular surface parameters and subjective symptoms in the MLE Group and the non-MLE Group before and after BoNT-A injection.


		Baseline (M (SD))₀	One week (M (SD))	(M (SD))	One month (M (SD))	(M (SD))	Three months (M (SD))	(M (SD))

Tear BUT, s	MLE	4.26 (2.83)	6.32 (3.57)	2.06 (4.33)	5.68 (3.00)	1.41 (3.61)	5.47 (3.20)	1.21 (2.65)
	Non-MLE	4.15 (2.71)	6.09 (4.20)	1.94 (4.76)	5.29 (2.69)	1.15 (3.53)	5.09 (2.21)	0.94 (2.35)
	Difference (95% CI)	0.12 (−0.31 to 0.55)		0.12 (−0.76 to 1.03)		0.26 (−0.33 to 0.86)		0.26 (−0.68 to 1.21)
	value	0.608		0.747		0.409		0.807

Schirmer I test, mm	MLE	8.59 (5.09)	13.82 (6.45)	5.24 (4.92)	12.09 (5.94)	3.50 (4.32)	9.53 (4.35)	0.94 (3.27)
	Non-MLE	8.91 (4.68)	11.21 (6.00)	2.29 (4.19)	10.76 (5.27)	1.85 (4.09)	9.32 (4.05)	0.41 (2.63)
	Difference (95% CI)	−0.32 (−1.46 to 0.81)		2.94 (1.41 to 4.47)		1.65 (0.20 to 3.10)		0.53 (−0.65 to 1.71)
	value	0.566		0.000		0.027		0.369

Lower lid TMH, mm	MLE	0.22 (0.13)	0.38 (0.17)	0.16 (0.17)	0.30 (0.14)	0.08 (0.12)	0.23 (0.13)	0.01 (0.07)
	Non-MLE	0.21 (0.09)	0.32 (0.14)	0.11 (0.13)	0.27 (0.12)	0.06 (0.11)	0.22 (0.09)	0.01 (0.06)
	Difference (95% CI)	0.01 (−0.02 to 0.04)		0.05 (0.01 to 0.10)		0.01 (−0.02 to 0.04)		0.00 (−0.02 to 0.02)
	value	0.660		0.012		0.336		0.535

Lagophthalmos height, mm	MLE	0	1.16 (0.95)	1.16 (0.95)	0.11 (0.38)	0.11 (0.38)	0	0
	Non-MLE	0	0.73 (0.81)	0.73 (0.81)	0.12 (0.39)	0.12 (0.39)	0	0
	Difference (95% CI)			0.44 (0.20 to 0.67)		−0.01 (−0.06 to 0.04)
	value			0.001		0.655

JRS score, points	MLE	7.70 (0.92)	1.82 (1.55)	−5.89 (1.65)	0.24 (0.83)	−7.45 (1.18)	0.88 (1.52)	−6.82 (1.65)
	Non-MLE	7.70 (0.92)	1.94 (1.48)	−5.76 (1.56)	0.30 (0.88)	−7.39 (1.20)	1.88 (1.60)	−5.82 (1.78)
	Difference (95% CI)			−0.12 (−0.29 to 0.05)		−0.06 (−0.18 to 0.06)		−1.00 (−1.35 to −0.65)
	value			0.157		0.317		0.000